Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

NCT01922050
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X, LEO 43204 Formulation 1 Dose Y, LEO 43204 Formulation 2 Dose XX, LEO 43204 Formulation 2 Dose YY, Placebo Formulation 1, Placebo Formulation 2
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Lomita, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay (SPF Assay 18677)

NCT02825017
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY 987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

NCT01325350
View directory record Official record
Conditions
Alopecia, Baldness
Interventions
bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 28, 2026, 10:59 PM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317
View directory record Official record
Conditions
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions
PVX-108, Placebo
Biological
Lead sponsor
Aravax Pty Ltd
Industry
Eligibility
4 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

NCT01987817
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules, Placebo powder provided in capsules
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT00664417
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00963508
View directory record Official record
Conditions
Pediculosis
Interventions
Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

NCT01769768
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LDE225, Wafarin, Bupropion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
HLD200 (methylphenidate hydrochloride)
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 28, 2026, 10:59 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

NCT07842640
View directory record Official record
Conditions
Chronic Weight Management
Interventions
ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay

NCT02822274
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

NCT00528021
View directory record Official record
Conditions
Pediculus Humanus Capitis, Head Lice
Interventions
Placebo, BGC20-0582
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 28, 2026, 10:59 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 10:59 PM EDT
Not listed Phase 1Phase 2 Interventional Results available

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

NCT03337087
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia

NCT00044889
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 28, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

BXCL501 After Stress to Increase Recovery Success

NCT06943404
View directory record Official record
Conditions
Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder
Interventions
BXCL501 (dexmedetomidine HCl), Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Jacksonville, Florida • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

NCT02646826
View directory record Official record
Conditions
Nocturia
Interventions
Placebo, Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
Other · Drug
Lead sponsor
Wellesley Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Brooklyn, New York • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

NCT02059915
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

NCT03554408
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
10-1074-LS, 3BNC117-LS
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 28, 2026, 10:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

NCT05975840
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 28, 2026, 10:59 PM EDT